Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 54:1150-1156, 2005
© 2005 by the American Diabetes Association, Inc.

Prevention of Type 2 Diabetes With Troglitazone in the Diabetes Prevention Program

The Diabetes Prevention Program Research Group*

From the George Washington University Biostatistics Center, Rockville, Maryland

The Diabetes Prevention Program (DPP) was a randomized clinical trial of prevention of type 2 diabetes in high-risk people. Troglitazone, an insulin-sensitizing agent, was used initially but was discontinued during the trial. Troglitazone therapy was compared with other DPP interventions, considering both the short-term "in-trial" results and the longer-term results after troglitazone were discontinued. From 1996 to 1998, participants were randomly assigned to treatment with metformin (n = 587), troglitazone (n = 585), double placebo (n = 582), or intensive lifestyle intervention (ILS) (n = 589). Because of concern regarding its liver toxicity, the troglitazone arm was discontinued in June 1998, after which follow-up of all participants continued. During the mean 0.9 year (range 0.5–1.5 years) of troglitazone treatment, the diabetes incidence rate was 3.0 cases/100 person-years, compared with 12.0, 6.7, and 5.1 cases/100 person-years in the placebo, metformin, and ILS participants (P < 0.001, troglitazone vs. placebo; P = 0.02, troglitazone vs. metformin; P = 0.18, troglitazone vs. ILS). This effect of troglitazone was in part due to improved insulin sensitivity with maintenance of insulin secretion. During the 3 years after troglitazone withdrawal, the diabetes incidence rate was almost identical to that of the placebo group. Troglitazone, therefore, markedly reduced the incidence of diabetes during its limited period of use, but this action did not persist. Whether other thiazolidinedione drugs used for longer periods can safely prevent diabetes remains to be determined.

Address correspondence and reprint requests to The Biostatistics Center, George Washington University, 6110 Executive Blvd., Suite 750, Rockville, MD 20852. E-mail: dppmail{at}biostat.bsc.gwu.edu


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 DiabetesHome page
K. J. Mather, T. Funahashi, Y. Matsuzawa, S. Edelstein, G. A. Bray, S. E. Kahn, J. Crandall, S. Marcovina, B. Goldstein, R. Goldberg, et al.
Adiponectin, Change in Adiponectin, and Progression to Diabetes in the Diabetes Prevention Program
Diabetes, April 1, 2008; 57(4): 980 - 986.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
Z. T. Bloomgarden
The Avandia Debate
Diabetes Care, September 1, 2007; 30(9): 2401 - 2408.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
H.-M. Jin and Y. Pan
Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy
Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1943 - 1949.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
J. L. Kitzmiller, L. Dang-Kilduff, and M. M. Taslimi
Gestational Diabetes After Delivery: Short-term management and long-term risks
Diabetes Care, July 1, 2007; 30(Supplement_2): S225 - S235.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
S. E. Kahn and B. Zinman
Point: Recent Long-Term Clinical Studies Support an Enhanced Role for Thiazolidinediones in the Management of Type 2 Diabetes
Diabetes Care, June 1, 2007; 30(6): 1672 - 1676.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
M. A. Abdul-Ghani, K. Williams, R. A. DeFronzo, and M. Stern
What Is the Best Predictor of Future Type 2 Diabetes?
Diabetes Care, June 1, 2007; 30(6): 1544 - 1548.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
T. A. Buchanan
(How) Can We Prevent Type 2 Diabetes?
Diabetes, June 1, 2007; 56(6): 1502 - 1507.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
M. B. Davidson
Clinical Implications of the DREAM Study: Response to Kanat
Diabetes Care, May 1, 2007; 30(5): e45 - e45.
[Full Text] [PDF]

Home page
 BMJHome page
V. M Montori, W. L Isley, and G. H Guyatt
Waking up from the DREAM of preventing diabetes with drugs
BMJ, April 28, 2007; 334(7599): 882 - 884.
[Full Text] [PDF]

Home page
 Endocr. Rev.Home page
B. L. Wajchenberg
{beta}-Cell Failure in Diabetes and Preservation by Clinical Treatment
Endocr. Rev., April 1, 2007; 28(2): 187 - 218.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. C. Florez, K. A. Jablonski, M. W. Sun, N. Bayley, S. E. Kahn, H. Shamoon, R. F. Hamman, W. C. Knowler, D. M. Nathan, D. Altshuler, et al.
Effects of the Type 2 Diabetes-Associated PPARG P12A Polymorphism on Progression to Diabetes and Response to Troglitazone
J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1502 - 1509.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. Tozzo, R. Ponticiello, J. Swartz, D. Farrelly, R. Zebo, G. Welzel, D. Egan, L. Kunselman, A. Peters, L. Gu, et al.
The Dual Peroxisome Proliferator-Activated Receptor {alpha}/{gamma} Activator Muraglitazar Prevents the Natural Progression of Diabetes in db/db Mice
J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 107 - 115.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
D. M. Nathan and M. Berkwits
Trials That Matter: Rosiglitazone, Ramipril, and the Prevention of Type 2 Diabetes
Ann Intern Med, March 20, 2007; 146(6): 461 - 463.
[Full Text] [PDF]

Home page
 AMERICAN JOURNAL OF LIFESTYLE MEDICINEHome page
M. J. Franz
The Evidence Is In: Lifestyle Interventions Can Prevent Diabetes
American Journal of Lifestyle Medicine, March 1, 2007; 1(2): 113 - 121.
[Abstract] [PDF]

Home page
 Diabetes CareHome page
D. M. Nathan, M. B. Davidson, R. A. DeFronzo, R. J. Heine, R. R. Henry, R. Pratley, and B. Zinman
Impaired Fasting Glucose and Impaired Glucose Tolerance: Implications for care
Diabetes Care, March 1, 2007; 30(3): 753 - 759.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
A. Gastaldelli, E. Ferrannini, Y. Miyazaki, M. Matsuda, A. Mari, and R. A. DeFronzo
Thiazolidinediones improve beta-cell function in type 2 diabetic patients
Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E871 - E883.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
C. Berry, J.-C. Tardif, and M. G. Bourassa
Coronary Heart Disease in Patients With Diabetes: Part I: Recent Advances in Prevention and Noninvasive Management
J. Am. Coll. Cardiol., February 13, 2007; 49(6): 631 - 642.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
R. S. Legro
A 27-Year-Old Woman With a Diagnosis of Polycystic Ovary Syndrome
JAMA, February 7, 2007; 297(5): 509 - 519.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
H. C. Gerstein
Point: If It Is Important to Prevent Type 2 Diabetes, It Is Important to Consider All Proven Therapies Within a Comprehensive Approach
Diabetes Care, February 1, 2007; 30(2): 432 - 434.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
J. Tuomilehto
Counterpoint: Evidence-Based Prevention of Type 2 Diabetes: The Power of Lifestyle Management
Diabetes Care, February 1, 2007; 30(2): 435 - 438.
[Full Text] [PDF]

Home page
 CirculationHome page
J. D. Brown and J. Plutzky
Peroxisome Proliferator Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets
Circulation, January 30, 2007; 115(4): 518 - 533.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
N. Rasouli, P. A Kern, E. A. Reece, and S. C. Elbein
Effects of pioglitazone and metformin on beta-cell function in nondiabetic subjects at high risk for type 2 diabetes
Am J Physiol Endocrinol Metab, January 1, 2007; 292(1): E359 - E365.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. E. Kahn, S. M. Haffner, M. A. Heise, W. H. Herman, R. R. Holman, N. P. Jones, B. G. Kravitz, J. M. Lachin, M. C. O'Neill, B. Zinman, et al.
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
N. Engl. J. Med., December 7, 2006; 355(23): 2427 - 2443.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
V. A. Fonseca and S. E. Kahn
Of Hopes and DREAMS: The Quest to Prevent Type 2 Diabetes
J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4762 - 4763.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
N. Fujii, N. Jessen, and L. J. Goodyear
AMP-activated protein kinase and the regulation of glucose transport
Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E867 - E877.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. C. Florez, K. A. Jablonski, N. Bayley, T. I. Pollin, P. I.W. de Bakker, A. R. Shuldiner, W. C. Knowler, D. M. Nathan, D. Altshuler, and the Diabetes Prevention Program Research Group
TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program.
N. Engl. J. Med., July 20, 2006; 355(3): 241 - 250.
[Abstract] [Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
A. Balasubramanyam, D. Hinnen, and W. Polonsky
Cardiovascular Event Prevention in the Person With Type 2 Diabetes: Case Examples for Identifying and Treating Multiple Risks
The Diabetes Educator, July 1, 2006; 32(Supplement_5): 163S - 173S.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
L. S. Phillips, W. S. Weintraub, D. C. Ziemer, P. Kolm, J. K. Foster, V. Vaccarino, M. K. Rhee, R. K. Budhwani, and J. M. Caudle
All Pre-Diabetes Is Not the Same: Metabolic and Vascular Risks of Impaired Fasting Glucose at 100 Versus 110 mg/dl: The Screening for Impaired Glucose Tolerance Study 1 (SIGT 1).
Diabetes Care, June 1, 2006; 29(6): 1405 - 1407.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
K. Esposito, M. Ciotola, D. Carleo, B. Schisano, F. Saccomanno, F. C. Sasso, D. Cozzolino, R. Assaloni, D. Merante, A. Ceriello, et al.
Effect of Rosiglitazone on Endothelial Function and Inflammatory Markers in Patients With the Metabolic Syndrome
Diabetes Care, May 1, 2006; 29(5): 1071 - 1076.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
K. Lobner, A. Knopff, A. Baumgarten, U. Mollenhauer, S. Marienfeld, M. Garrido-Franco, E. Bonifacio, and A.-G. Ziegler
Predictors of Postpartum Diabetes in Women With Gestational Diabetes Mellitus
Diabetes, March 1, 2006; 55(3): 792 - 797.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. H. Xiang, R. K. Peters, S. L. Kjos, A. Marroquin, J. Goico, C. Ochoa, M. Kawakubo, and T. A. Buchanan
Effect of Pioglitazone on Pancreatic {beta}-Cell Function and Diabetes Risk in Hispanic Women With Prior Gestational Diabetes
Diabetes, February 1, 2006; 55(2): 517 - 522.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. B. Meigs, C. J. O'Donnell, G. H. Tofler, E. J. Benjamin, C. S. Fox, I. Lipinska, D. M. Nathan, L. M. Sullivan, R. B. D'Agostino, and P. W.F. Wilson
Hemostatic Markers of Endothelial Dysfunction and Risk of Incident Type 2 Diabetes: The Framingham Offspring Study
Diabetes, February 1, 2006; 55(2): 530 - 537.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
D. M. Kendall
Thiazolidinediones: The case for early use
Diabetes Care, January 1, 2006; 29(1): 154 - 157.
[Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
P. O. Szapary, L. T. Bloedon, F. F. Samaha, D. Duffy, M. L. Wolfe, D. Soffer, M. P. Reilly, J. Chittams, and D. J. Rader
Effects of Pioglitazone on Lipoproteins, Inflammatory Markers, and Adipokines in Nondiabetic Patients with Metabolic Syndrome
Arterioscler. Thromb. Vasc. Biol., January 1, 2006; 26(1): 182 - 188.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
American Diabetes Association
Standards of Medical Care in Diabetes-2006
Diabetes Care, January 1, 2006; 29(suppl_1): S4 - S42.
[Full Text] [PDF]

Home page
 CirculationHome page
S. M. Grundy, J. I. Cleeman, S. R. Daniels, K. A. Donato, R. H. Eckel, B. A. Franklin, D. J. Gordon, R. M. Krauss, P. J. Savage, S. C. Smith Jr, et al.
Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
Circulation, October 25, 2005; 112(17): 2735 - 2752.
[Full Text] [PDF]

Home page
 DiabetesHome page
B. Staels and J.-C. Fruchart
Therapeutic Roles of Peroxisome Proliferator-Activated Receptor Agonists
Diabetes, August 1, 2005; 54(8): 2460 - 2470.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2005 by the American Diabetes Association.